4-吗啉苯基乙二醛 | 361344-43-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 4-吗啉苯基乙二醛
• 英文名称: (4-morpholin-4-ylphenyl)(oxo)acetaldehyde
• 英文别名: 2-(4-morpholinophenyl)-2-oxoacetaldehyde；4-Morpholinophenylglyoxal；2-(4-morpholin-4-ylphenyl)-2-oxoacetaldehyde
• CAS: 361344-43-6
• 化学式: C₁₂H₁₃NO₃
• 分子量: 219.24
• InChiKey: YYRFNKUMQLISOP-UHFFFAOYSA-N

物化性质

• 沸点：
  386.5±42.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4-吗啉苯基乙二醛 在 三乙胺 、 lithium chloride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 12.5h， 生成 2-{[3-(4-morpholin-4-yl-phenyl)-5-oxo-1-pentyl-2,5-dihydro-1H-pyrrol-2-carbonyl]-amino}-3-phenyl-propionic acid methyl ester
  参考文献：
  名称：

  Highly Substituted Pyrrolidinones and Pyridones by 4-CR/2-CR Sequence

  摘要：

  By combining a Ugi four-component reaction of isocyanides, phosphonoacetic acids, primary amines, and glyoxals or alternatively 3-keto aldehydes with a subsequent Wittig ring-closing reaction (using the Horner/Wadsworth/Emmons variant (HWE)), highly substituted 5-oxo-2,5dihydro-1H-pyrrole-2-carboxylic acid amides and 6-oxo-1,2,3,6-tetrahydro-pyridine-2-carboxylic acid amides can be assembled, respectively. The corresponding tandem of a Passerini reaction on 3-keto aldehydes and subsequent Wittig ring closure does not afford the expected six-membered 6-oxo-3,6-dihydro-2H-pyran-2-carboxylic acid amides but instead leads to the formation of 4-oxo-pent-2-enoic acid amides via an elimination route.

  DOI：

  10.1021/ol035787n
• 作为产物：
  描述：

  4-(4-吗啉基)苯乙酮 在 selenium(IV) oxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 4-吗啉苯基乙二醛
  参考文献：
  名称：

  可见光促进 1,4-二氢吡啶的三氟甲基硫醇化和三氟甲基硒化

  摘要：

  我们报告了 1,4-二氢吡啶与S -（三氟甲基）4-甲基苯硫代磺酸盐和Se -（三氟甲基）4-甲基苯磺酰硒酸盐在可见光照射下的无金属三氟甲基硫醇化和三氟甲基硒化。这种转化可以被广泛的官能团所接受，并为三氟甲基硫酯和三氟甲基硒酯的合成提供了一种替代的绿色策略。

  DOI：

  10.1021/acs.joc.2c02348

文献信息

• Visible-Light-Promoted Photocatalyst-Free Hydroacylation and Diacylation of Alkenes Tuned by NiCl₂·DME
  作者：Xinxin Zhao、Bing Li、Wujiong Xia

  DOI：10.1021/acs.orglett.9b04595

  日期：2020.2.7

  4-dihydropyridines via an acyl radical addition and hydrogen atom transfer pathway under photocatalyst-free conditions. The efficiency was highlighted by wide substrate scope, good to high yields, successful scale-up experiments, and expedient preparation of highly functionalized ketone derivatives. In addition, this protocol allows for the synthesis of 1,4-dicarbonyl compounds through alkene diacylation in the presence

  在这里，我们描述了一种可见光促进的加氢酰化策略，该策略有助于在无光催化剂的条件下，通过酰基加成和氢原子转移途径，从烯烃和4-酰基-1,4-二氢吡啶制备酮。广泛的底物范围，良好至高收率，成功的按比例放大实验以及方便地制备高度官能化的酮衍生物等突出了效率。另外，该方案允许在NiCl2·DME存在下通过烯烃二酰化反应合成1,4-二羰基化合物。
• Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines
  作者：László Kékesi、Anna Sipos、Gábor Németh、János Pató、Nóra Breza、Ferenc Baska、László Őrfi、György Kéri

  DOI：10.1016/j.bmcl.2013.09.005

  日期：2013.11

  novel pyrido[2,3-b]pyrazines were synthesized as potential antitumor agents for erlotinib-resistant tumors. Known signal inhibitor compounds from our Nested Chemical Library were tested in phenotypic assays on erlotinib-sensitive PC9 and erlotinib-resistant PC9-ER cell lines to find a compound class to be active on erlotinib resistant cell lines. Based on the screening data, novel pyrido[2,3-b]pyrazines

  合成了一系列新型的吡啶并[2,3- b ]吡嗪类化合物，作为抗厄洛替尼耐药肿瘤的潜在抗肿瘤药。我们对巢式化学文库中已知的信号抑制剂化合物进行了表型分析，以对厄洛替尼敏感的PC9和耐厄洛替尼的PC9-ER细胞系进行了测试，以找出在耐厄洛替尼的细胞系中具有活性的化合物类别。根据筛选数据，设计合成了新型吡啶并[2,3- b ]吡嗪。探索了杂芳族部分在7位上的取代基位置的影响以及吡啶并吡嗪核心2位未取代的重要性。化合物7n的IC 50抑制PC9的值为0.09μM，抑制PC9-ER的值为0.15μM。我们发现这些结构的一些先导化合物克服了对厄洛替尼的耐药性，这可能成为有望与EGFR T790M突变抗NSCLC的候选药物。这些新型化合物克服厄洛替尼耐药性的作用机制中涉及的信号网络仍有待阐明。
• [EN] PYRIDOPYRAZINES AS ANTICANCER AGENTS<br/>[FR] PYRIDOPYRAZINES UTILISÉS EN TANT QU'AGENTS ANTINÉOPLASIQUES
  申请人：VICHEM CHEMIE KUTATÓ KFT

  公开号：WO2014106763A1

  公开（公告）日：2014-07-10

  The present invention relates to pyridopyrazine derivatives and solvates, hydrates and pharmaceutically acceptable salts thereof, the use of them in the prevention and/or the treatment of cancer diseases, as well as pharmaceutical compositions containing at least one of them as pharmaceutically active agent(s) together with pharmaceutically acceptable carrier, excipient and/or diluents, especially for the prevention and/or treatment of cancer diseases.˙

  本发明涉及吡啶吡嗪衍生物及其溶剂化物、水合物和药用可接受的盐，其在预防和/或治疗癌症疾病中的使用，以及含有至少一种作为药用活性剂的药用组合物，与药用可接受载体、赋形剂和/或稀释剂一起，特别用于预防和/或治疗癌症疾病。
• Design and Synthesis of 2-Acylbenzothiazoles via In Situ Cross-Trapping Strategy from Benzothiazoles with Aryl Ketones
  作者：Qinghe Gao、Xia Wu、Fengcheng Jia、Meicai Liu、Yanping Zhu、Qun Cai、Anxin Wu

  DOI：10.1021/jo302754c

  日期：2013.3.15

  An I-2/KOH synergistically promoted direct ring-opening aroylation of benzothiazoles with aryl ketones has been discovered. Aryl ketones were seen to act as carbonyl sources to construct 2-acylbenzothiazoles. This reaction could provide an example for the convergent integration of self-labor domino sequences based on an in situ cross-trapping strategy.
• Discovery of 4-Amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-<i>d</i>]pyrimidine, an Orally Active, Non-Nucleoside Adenosine Kinase Inhibitor
  作者：Chih-Hung Lee、Meiqun Jiang、Marlon Cowart、Greg Gfesser、Richard Perner、Ki Hwan Kim、Yu Gui Gu、Michael Williams、Michael F. Jarvis、Elizabeth A. Kowaluk、Andrew O. Stewart、Shripad S. Bhagwat

  DOI：10.1021/jm000314x

  日期：2001.6.1

  Adenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation, inhibition of adenosine kinase (AK), the primary metabolic enzyme for ADO, selectively increases ADO concentrations at sites of tissue trauma and enhances the analgesic and antiinflammatory actions of ADO. Optimization of the high-throughput screening lead, 4-amino-7-aryl-substituted pteridine (5) (AK IC50 = 440 nM), led to the identification of compound 21 (4-amino-5-(3-bromophenyl)-7-(6-morpholino- pyridin-3-yl)pyrido [2,3-d]pyrimidine, ABT-702), a novel, potent (AK IC50 = 1.7 nM) non-nucleoside AK inhibitor with oral. activity in animal models of pain and inflammation.